混合性血脂异常的联合药物治疗  

作　　者：夏剑波 欧胜伟 

机构地区：[1]益阳医学高等专科学校附属医院,湖南益阳413000

出　　处：《中外医疗》2011年第16期3-4,共2页China & Foreign Medical Treatment

摘　　要：目的探讨混合性血脂异常的联合药物治疗方法及疗效。方法将本院2009年1月至2010年1月期间混合性脂血异常的165例患者随机分为辛伐他汀对照组83例和联合药物治疗组82例。对照组:辛伐他汀20mg/次,每晚口服;治疗组:使用非诺贝特200mg/次,辛伐他汀10mg/次联合治疗,每日清晨口服,12周为1个疗程。结果 2组治疗前后血脂参数TC、LDL-C、HDL-C与TG与对照组均有显著差异,t=2.032、2.141、1.998、2.065,P<0.05,提示存在显著差异性,有统计学意义。结论辛伐他汀联合非诺贝特治疗混合性血脂异常疗效确切,值得临床推广应用。Objective To investigate the combined mixed dyslipidemia and efficacy of drug treatment.Methods Hospital January,2009 is to January,2010abnormal blood fat during the mixing of the165patients were randomly divided into simvastatin group and83cases 82 cases of combined drug treatment group;observation groups：simvastatin20mg/times,orally every night;treatment group：fenofibrate 200mg/times,simvastatin10mg/joint treatment,daily morning oral,12weeks/course.Results Both before and after treatment lipid parameters TC,LDL-C,HDL-C and TG with the control group were significantly different,t=2.032、2.141、1.998、2.065,P0.05,suggests the presence of significant differences,there was significance.Conclusion Simvastatin and fenofibrate treatment of mixed dyslipidemia effective,worthy of clinical application.

关 键 词：混合性血脂异常 

分 类 号：R589[医药卫生—内分泌]